共 50 条
Gynecologic Cancer InterGroup (GCIG) Consensus Review for Ovarian Sex Cord Stromal Tumors
被引:71
|作者:
Ray-Coquard, Isabelle
[1
]
Brown, Jubilee
[2
]
Harter, Philipp
[3
]
Provencher, Diane M.
[4
]
Fong, Peter C.
[5
]
Maenpaa, Johanna
[6
]
Ledermann, Jonathan A.
[7
]
Emons, Gunter
[8
]
Rigaud, Dominique Berton
[9
]
Glasspool, Rosalind M.
[10
]
Mezzanzanica, Delia
[11
]
Colombo, Nicoletta
[12
]
机构:
[1] Ctr Leon Berard, F-69373 Lyon 08, France
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[3] Kliniken Essen Mitte, Essen, Germany
[4] CHUM Hop Notre Dame, Montreal, PQ, Canada
[5] Univ Auckland, FMHS, Auckland 1, New Zealand
[6] Tampere Univ Hosp, Tampere, Finland
[7] UCL Canc Inst, London, England
[8] Univ Med, Gottingen, Germany
[9] Inst Cancerol Ouest Rene Gauducheau, St Herblain, France
[10] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[11] Fdn IRCCS Inst Nazl Tumori, Milan, Italy
[12] Univ Milano Bicocca, Milan, Italy
关键词:
Rare tumor;
Sex cord stromal tumors;
Molecular analysis;
First-line treatment;
Metastatic disease;
GRANULOSA-CELL TUMORS;
DICER1;
MUTATIONS;
BEVACIZUMAB;
EXPRESSION;
MANAGEMENT;
FOXL2;
GENE;
RARE;
D O I:
10.1097/IGC.0000000000000249
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
Sex cord stromal tumors (SCST) are rare cancers of the ovarian area in adults. They constitute a heterogeneous group of tumors that develop from the sex cords and the ovarian stroma. These tumors are detected typically at an early stage, and they may recur as late as 30 years after the initial treatment. Because 70% of the patients present with stage I tumors, surgery represents the most important therapeutic arm. There are no data to support any kind of postoperative adjuvant treatment for patients with stage IA or IB SCSTs, given the indolent nature of these neoplasms and the overall good prognosis. The long natural history of the disease may lead to repeated surgical procedure should a relapse occurs. Platinum-based chemotherapy is currently used for patients with advanced stage SCSTs or recurrent disease, with an overall response rate of 63% to 80%. The indolent nature of SCSTs with the tendency for late recurrence requires long-term follow-up.
引用
收藏
页码:S42 / S47
页数:6
相关论文